NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
24 April 2025
| Name: | CHIMERIC THERAPEUTICS LIMITED (CHM) |
| ISIN: | AU0000121576 |
| Date of Listing: | 18 January 2021 |
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
This is a current registered entity, not in any form of external administration to our knowledge.Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
Boardroom Pty Ltd
Level 8, 210 George Street, Sydney NSW 2000
Tel : +61 2 9290 9600 or 1300 737 760
Fax : +61 2 9279 0664 or 1300 653 459
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Chimeric Therapeutics Limited will be lifted immediately following the release by CHM of an announcement regarding a capital raising that was not undertaken and subsequently an intention to conduct an entitlement offer. | 04/03/2025 |
The company plans to undertake an Entitlement Offer to raise $3.2 million at a pro rata non-renounceable price of $0.005 per share. The offer will be completed by issuing 2 new shares for every 5 existing shares held by eligible shareholders. The funds will support the development of Chimeric's CHM CDH17 Phase 1/2 clinical trial. The offer is subject to shareholder approval. | 04/03/2025 |
The securities of Chimeric Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CHM, pending the release of an announcement regarding a capital raising. | 03/03/2025 |
The suspension of trading in the securities of Chimeric Therapeutics Limited will be lifted from the commencement of trading on Tuesday, 22 October 2024 following lodgement of its annual report for the year ended 30 June 2024. | 21/10/2024 |
The company lodges its Environmental Social Governance Report. | 21/10/2024 |
The company lodges its Corporate Governance Statement and Appendix 4G. | 21/10/2024 |
The company lodges its 2024 Annual Report. | 21/10/2024 |
The company has received commitments for a $5 million capital raising through a two-tranche placement to sophisticated investors. The offer price is $0.008 per Placement Share, with 125 million Placement Shares to be issued to Executive Chairman Paul Hopper. The remaining shares will be issued at an extraordinary general meeting. The placement is expected to occur on 23 October 2024, with normal trading starting on 24 October 2024. | 21/10/2024 |
The Annual General Meeting of the company will take place on November 12, 2024, at Level 3, 62 Lygon Street, Carlton, Victoria 3053, with registration starting at 10:45 am. | 14/10/2024 |
The company lodges its 2024 Annual Report update. | 11/10/2024 |
The company has reported a Complete Response from an Acute Myelogenous Leukemia patient in its CHM CORE-NK + Vactosertib Phase 1b clinical trial. The trial, led by Dr Eva Selfridge at UH Seidman Cancer Center in Ohio, is the first to assess NK cells in combination with Vactosertib in patients with advanced colorectal and blood cancers. The patient will continue on study and be monitored for up to 15 years, a standard FDA requirement for all cell therapy trials. The trial is currently enrolled in three patients, with the goal of enrolling 12 patients. | 07/10/2024 |
The company lodges its 2024 Annual Report update. | 04/10/2024 |
The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 1 October 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Monday, 30 September 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 01/10/2024 |
The suspension of trading in the options (ASX: CHMO) of Chimeric Therapeutics Limited will be lifted immediately. | 28/03/2022 |
The options of Chimeric Therapeutics Limited will be suspended immediately, in accordance with Listing Rule 17.3, as deferred settlement trading will not be made available for them, as noted in CHM's Prospectus, announced to the market on 21 February 2022. The options are expected to be quoted on a normal settlement basis on Monday, 28 March 2022. The suspension only applies to the CHM's options and does not apply to any other quoted securities of CHM. | 21/03/2022 |
listed entity carried for record purposes only | 18/01/2021 |
The suspension of trading in the securities of Chimeric Therapeutics Limited will be lifted immediately following the release by CHM of an announcement regarding a capital raising that was not undertaken and subsequently an intention to conduct an entitlement offer. | 04/03/2025 |
The company plans to undertake an Entitlement Offer to raise $3.2 million at a pro rata non-renounceable price of $0.005 per share. The offer will be completed by issuing 2 new shares for every 5 existing shares held by eligible shareholders. The funds will support the development of Chimeric's CHM CDH17 Phase 1/2 clinical trial. The offer is subject to shareholder approval. | 04/03/2025 |
The securities of Chimeric Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CHM, pending the release of an announcement regarding a capital raising. | 03/03/2025 |
The suspension of trading in the securities of Chimeric Therapeutics Limited will be lifted from the commencement of trading on Tuesday, 22 October 2024 following lodgement of its annual report for the year ended 30 June 2024. | 21/10/2024 |
The company lodges its Environmental Social Governance Report. | 21/10/2024 |
The company lodges its Corporate Governance Statement and Appendix 4G. | 21/10/2024 |
The company lodges its 2024 Annual Report. | 21/10/2024 |
The company has received commitments for a $5 million capital raising through a two-tranche placement to sophisticated investors. The offer price is $0.008 per Placement Share, with 125 million Placement Shares to be issued to Executive Chairman Paul Hopper. The remaining shares will be issued at an extraordinary general meeting. The placement is expected to occur on 23 October 2024, with normal trading starting on 24 October 2024. | 21/10/2024 |
The Annual General Meeting of the company will take place on November 12, 2024, at Level 3, 62 Lygon Street, Carlton, Victoria 3053, with registration starting at 10:45 am. | 14/10/2024 |
The company lodges its 2024 Annual Report update. | 11/10/2024 |
The company has reported a Complete Response from an Acute Myelogenous Leukemia patient in its CHM CORE-NK + Vactosertib Phase 1b clinical trial. The trial, led by Dr Eva Selfridge at UH Seidman Cancer Center in Ohio, is the first to assess NK cells in combination with Vactosertib in patients with advanced colorectal and blood cancers. The patient will continue on study and be monitored for up to 15 years, a standard FDA requirement for all cell therapy trials. The trial is currently enrolled in three patients, with the goal of enrolling 12 patients. | 07/10/2024 |
The company lodges its 2024 Annual Report update. | 04/10/2024 |
The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 1 October 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Monday, 30 September 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 01/10/2024 |
The suspension of trading in the options (ASX: CHMO) of Chimeric Therapeutics Limited will be lifted immediately. | 28/03/2022 |
The options of Chimeric Therapeutics Limited will be suspended immediately, in accordance with Listing Rule 17.3, as deferred settlement trading will not be made available for them, as noted in CHM's Prospectus, announced to the market on 21 February 2022. The options are expected to be quoted on a normal settlement basis on Monday, 28 March 2022. The suspension only applies to the CHM's options and does not apply to any other quoted securities of CHM. | 21/03/2022 |
listed entity carried for record purposes only | 18/01/2021 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 04/07/2022 | George Matcham | 342,070 | $0.098 | $33,523 |
| 29/06/2022 | Leslie Chong | 30,000 | $0.098 | $2,940 |
| 03/12/2021 | Paul Hopper | 375,000 | $0.263 | $98,438 |
| 04/08/2021 | George Matcham | 500,000 | $0.335 | $167,500 |
| 08/03/2021 | Cindy Elkins | 24,800 | $0.318 | $7,881 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Paul Hopper | Executive Chairman | 04/02/2020 |
| Rebecca McQualter | CEO | 12/11/2024 |
| Phillip Hains | CFO, Company Secretary | 06/10/2020 |
| Lesley Russell | Non Exec Director | 18/01/2021 |
| Eric Sullivan | Non Exec Director | 30/08/2023 |
| Nathan Jong | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Jennifer Chow | Managing Director, CEO | 30/08/2021 | 24/05/2024 |
| Cindy Elkins | Non Exec Director | 01/02/2021 | 30/08/2023 |
| George Matcham | Non Exec Director | 05/07/2021 | 03/08/2023 |
| Leslie Chong | Non Exec Director | 18/01/2021 | 12/07/2023 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
